65,437 trials
Breast Cancer
Primary: Change in Proliferation of Breast Epithelial Cells Obtained by Random Periareolar Fine Needle Aspiration. — -2.3 Change in % of cells positive for Ki-67
Influenza
Primary: Number of Seroconverted Subjects Against A/Indonesia/5/2005 (H5N1) — 1427; 1; 293; 1 Subjects
Stroke
Primary: Fugl-Meyer Upper Limb Coordination Scale (FMUE) — 27.75; 48.50 units on a scale — p=.0001
Jaw, Edentulous, Partially
Primary: Implant Survival Rate — 96.25 percentage of implants
Weight Loss · Body Weight
Primary: Adherence to Weight Tracking Instructions — 98.3; 96.7 percentage of postcards returned — p=.15
Influenza
Primary: Number of Seroconverted Subjects for Haemagglutination Inhibition (HI) Antibodies Against the A/Turkey/Turkey/1/2005 (A/Turkey) Virus Strain. — 71; 81; 73; 65 Subjects
Asthma
Primary: Peak FEV1 Within 3 Hours Post-dose Response — 0.053; 0.289; 0.250; 0.266 Litre — p=<0.0001
Schistosomiasis
Primary: Mean Newborn Birth Weight — 2.85; 2.85 kilograms — p=0.988
Femoral Neck Fractures · Hip Fractures
Primary: Number of Participants Reporting at Least One NRS Rating — 18; 18 Participants
Schizophrenia
Primary: Negative Symptoms Measured on Positive and Negative Syndrome Scale (PANSS) — 17.63; 18.29; 17.06; 17.08 units on a scale
Influenza
Primary: Number of Seroconverted Subjects Against the A/Indonesia/5/2005 (H5N1) Strain of Influenza Disease. — 13; 140; 131; 135 Participants
Asthma
Primary: Peak FEV1 Within 3 Hours Post-dose Response — 0.075; 0.287; 0.244; 0.252 Litre — p=<0.0001
Healthy
Primary: Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE) During the Treatment Period — 32; 6; 103; 10 Participants
Renal Transplantation
Primary: Comparison of Average Immunosuppressant Therapy Adherence for 12-month Study Period — 0.88; 0.81 medication possession ratio (proportion) — p=<0.05
Morbid Obesity
Primary: Percent Excess Weight Change From Baseline to 24 Months — 39.8 percent of excess weight at baseline — p=<0.0001